Skip to main content

Table 2 VARC-2 complications (30 days)

From: The association of diabetes mellitus treated with oral antidiabetic drugs and insulin with mortality after transcatheter valve implantation: a 3-year follow-up of the TAVIK registry

 

Without diabetes (n = 1337)

Diabetes on OAD (n = 387)

Diabetes on insulin (n = 276)

p-value

HR (95% CI)*

p-value*

Total mortality

68 (5.1)

17 (4.4)

21 (7.6)

0.255

1.05 (0.69–1.60)

0.814

 Cardiovascular death

45 (3.4)

15 (3.9)

15 (5.4)

0.212

0.91 (0.56–1.48)

0.711

 Noncardiovascular death

23 (1.7)

2 (0.5)

6 (2.2)

0.160

1.46 (0.64–3.36)

0.369

Myocardial infarction

14 (1.0)

7 (1.8)

4 (1.4)

0.379

0.58 (0.26–1.33)

0.201

Stroke

78 (5.8)

14 (3.6)

13 (4.7)

0.110

1.49 (0.94–2.35)

0.088

 Major/disabling stroke

29 (2.2)

8 (2.1)

8 (2.9)

0.731

0.94 (0.50–1.76)

0.854

 Minor stroke

49 (3.7)

6 (1.6)

5 (1.8)

0.046

2.19 (1.11–4.3)

0.023

Bleeding

254 (19.0)

71 (18.3)

58 (21.0)

0.809

0.96 (0.75–1.22)

0.735

 Life-threatening or major

127 (9.5)

33 (8.5)

31 (11.2)

0.936

1.02 (0.73–1.46)

0.927

 Minor

127 (9.5)

38 (9.8)

27 (9.8)

0.872

0.91 (0.66–1.26)

0.584

Renal complications

302 (22.6)

115 (29.7)

101 (36.6)

< 0.001

1.46 (1.18–1.81)

< 0.001

 Stage 2/3

36 (2.7)

13 (3.4)

13 (4.7)

0.170

0.73 (0.43–1.24)

0.248

Vascular complications

123 (9.2)

39 (10.1)

22 (8.0)

0.652

0.94 (0.67–1.31)

0.713

 Major

39 (2.9)

14 (3.6)

12 (4.3)

0.428

0.74 (0.44–1.24)

0.255

 Minor

84 (6.3)

25 (6.5)

10 (3.6)

0.211

1.09 (0.72–1.66)

0.676

New PPM implantation

175/1167 (15.0)

45/340 (13.2)

43/228 (18.9)

0.180

0.96 (0.72–1.27)

0.753

  1. VARC-2 criteria, Kappetein et al. [45]
  2. PPM primary pacemaker
  3. * Adjustment of significant basic parameters (age, ejection fraction, previous CABG, coronary artery disease, major neurological deficits, renal disease and frailty) between patients with and without DM